aspirin has been researched along with Barrett Epithelium in 58 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), low-dose aspirin and statins may decrease the risk of oesophageal adenocarcinoma (OAC) among patients with Barrett's oesophagus (BO)." | 7.81 | NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. ( Coloma, PM; Kuipers, EJ; Masclee, GM; Spaander, MC; Sturkenboom, MC, 2015) |
| "Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with Barrett's esophagus." | 7.80 | Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model. ( Cebrián, C; Esquivias, P; García-González, MA; Lanas, A; Morandeira, A; Ortego, J; Piazuelo, E; Santander, S, 2014) |
| "Non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), low-dose aspirin and statins may decrease the risk of oesophageal adenocarcinoma (OAC) among patients with Barrett's oesophagus (BO)." | 3.81 | NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. ( Coloma, PM; Kuipers, EJ; Masclee, GM; Spaander, MC; Sturkenboom, MC, 2015) |
| "Data suggest that aspirin, statins, or a combination of the two drugs may lower the progression of Barrett's esophagus to esophageal adenocarcinoma." | 3.80 | Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. ( Choi, SE; Hur, C; Kong, CY; Perzan, KE; Tramontano, AC, 2014) |
| "Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with Barrett's esophagus." | 3.80 | Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model. ( Cebrián, C; Esquivias, P; García-González, MA; Lanas, A; Morandeira, A; Ortego, J; Piazuelo, E; Santander, S, 2014) |
| " Male gender, smoking, alcohol drinking, consumption of coffee, large waist circumference, infrequent medication of antacids, aspirin and NSAIDs, infrequent and mild GERD symptoms were all significantly associated with ED on univariate analysis." | 3.77 | [Clinical characteristics of gastroesophageal reflux disease with esophageal injury in korean: focusing on risk factors]. ( Cho, KB; Jang, BI; Jeon, SW; Jung, JT; Jung, MK; Kim, ES; Kim, EY; Kim, KO; Kim, SK; Kwon, JG; Lee, JH; Lee, SH; Lee, SJ; Park, CK; Park, KS; Seo, HE; Yang, CH, 2011) |
| "Although evidence suggests that aspirin and celecoxib may reduce the risk of esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE), these drugs can also cause harmful side effects." | 3.74 | Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. ( Broughton, DE; Gazelle, GS; Hur, C; Nishioka, NS; Ozanne, E; Yachimski, P, 2008) |
| "Candidates for chemoprevention in Barrett's esophagus have long been suggested and there has been observational data to support many drugs, including statins, hormone replacement therapy, metformin, proton pump inhibitor therapy, and aspirin." | 2.72 | Current Status of Chemoprevention in Barrett's Esophagus. ( El-Serag, HB; Moayyedi, P, 2021) |
| "To compare the effects of aspirin and rofecoxib when administered with esomeprazole on prostaglandin E(2) production, cyclo-oxygenase-2 expression and proliferating cell nuclear antigen expression in patients with Barrett's oesophagus." | 2.72 | The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett's oesophagus. ( Kaur, B; Levine, D; Sood, S; Traxler, B; Triadafilopoulos, G; Weston, A, 2006) |
| "Abdominal obesity, independently of gastroesophageal reflux disease symptoms, is associated with increased risk of Barrett's esophagus and this association is likely mediated by high levels of leptin and insulin." | 2.53 | Determination of risk for Barrett's esophagus and esophageal adenocarcinoma. ( Thrift, AP, 2016) |
| "Barrett's metaplasia is one of the commonest premalignant lesions in the western world following colorectal adenomas." | 2.47 | Acid reflux and oesophageal cancer. ( Jankowski, J; Nicholson, A, 2011) |
| "In patients with Barrett's esophagus, medical treatment is necessary for the control of reflux symptom, healing of accompanying erosive esophagitis, and prevention of carcinogenesis." | 2.43 | [Medical treatment of Barrett's esophagus]. ( Kinoshita, Y; Yuki, T, 2005) |
| "Barrett esophagus is a premalignant change of the esophagus; however, malignant transformation to esophageal adenocarcinoma is rare in patients without dysplasia." | 1.72 | Barrett Esophagus: Rapid Evidence Review. ( Bryce, C; Bucaj, M; Gazda, R, 2022) |
| "Cases had a new diagnosis of Barrett's esophagus between October 2002 and September 2005; controls were members without a diagnosis of Barrett's esophagus." | 1.42 | Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus. ( Corley, DA; Schneider, JL; Zhao, WK, 2015) |
| "18), and no dose-response effects were present in either analysis." | 1.37 | The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. ( Green, AC; Pandeya, N; Smith, KJ; Thrift, AP; Webb, PM; Whiteman, DC, 2011) |
| "examined Barrett's esophagus patient preferences for cancer chemoprevention with either aspirin or celecoxib." | 1.35 | Chemoprevention and Barrett's esophagus: decisions, decisions. ( Falk, GW; Jankowski, J, 2008) |
| "It has been suggested that Barrett's esophagus (BE) is associated with an increased risk of developing colorectal neoplasia, but this has not been reported consistently." | 1.33 | Colorectal neoplasia in veterans is associated with Barrett's esophagus but not with proton-pump inhibitor or aspirin/NSAID use. ( Kuipers, EJ; Sahbaie, P; Siersema, PD; Simpson, PW; Steyerberg, EW; Triadafilopoulos, G; Yu, S, 2006) |
| "In total, 230 reflux esophagitis, 224 Barrett's esophagus, and 227 esophageal adenocarcinoma and 260 population controls were recruited." | 1.33 | Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. ( Anderson, LA; Comber, H; Ferguson, HR; Johnston, BT; McGuigan, J; Murphy, SJ; Murray, LJ; Reynolds, JV; Watson, RG, 2006) |
| "Uninvestigated dyspepsia is common in family practice." | 1.32 | The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study. ( Armstrong, D; Barkun, AN; Chakraborty, B; Chiba, N; Daniels, S; Escobedo, S; Sinclair, P; Thomson, AB; Van Zanten, SJ; White, RJ, 2003) |
| "Aspirin therapy was more effective and less costly than no therapy, resulting in 0." | 1.32 | Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. ( Gazelle, GS; Hur, C; Nishioka, NS, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.45) | 18.2507 |
| 2000's | 20 (34.48) | 29.6817 |
| 2010's | 33 (56.90) | 24.3611 |
| 2020's | 3 (5.17) | 2.80 |
| Authors | Studies |
|---|---|
| Bryce, C | 1 |
| Bucaj, M | 1 |
| Gazda, R | 1 |
| Zhang, T | 1 |
| Wang, Q | 1 |
| Ma, WY | 1 |
| Wang, K | 2 |
| Chang, X | 1 |
| Johnson, ML | 1 |
| Bai, R | 1 |
| Bode, AM | 1 |
| Foster, NR | 2 |
| Falk, GW | 3 |
| Limburg, PJ | 2 |
| Iyer, PG | 1 |
| Dong, Z | 1 |
| Moayyedi, P | 3 |
| El-Serag, HB | 3 |
| Zhao, Z | 1 |
| Yin, Z | 1 |
| Zhang, C | 1 |
| Huo, X | 1 |
| Zhang, X | 1 |
| Yu, C | 1 |
| Cheng, E | 1 |
| Zhang, Q | 1 |
| Dunbar, KB | 1 |
| Pham, TH | 1 |
| Lynch, JP | 1 |
| Wang, DH | 1 |
| Bresalier, RS | 1 |
| Spechler, SJ | 1 |
| Souza, RF | 1 |
| Thota, PN | 1 |
| Hvid-Jensen, F | 1 |
| Drewes, AM | 1 |
| Jankowski, JAZ | 1 |
| de Caestecker, J | 1 |
| Love, SB | 1 |
| Reilly, G | 1 |
| Watson, P | 1 |
| Sanders, S | 1 |
| Ang, Y | 1 |
| Morris, D | 1 |
| Bhandari, P | 1 |
| Brooks, C | 1 |
| Attwood, S | 2 |
| Harrison, R | 2 |
| Barr, H | 2 |
| Husain, NS | 1 |
| Marshall, JK | 1 |
| Fitzgerald, RC | 1 |
| Corley, DA | 4 |
| Choi, SE | 1 |
| Perzan, KE | 1 |
| Tramontano, AC | 1 |
| Kong, CY | 2 |
| Hur, C | 5 |
| Peura, DA | 1 |
| Wilcox, CM | 1 |
| Cowie, A | 1 |
| Noble, F | 1 |
| Underwood, T | 1 |
| Esquivias, P | 1 |
| Cebrián, C | 1 |
| Morandeira, A | 1 |
| Santander, S | 1 |
| Ortego, J | 1 |
| García-González, MA | 1 |
| Lanas, A | 1 |
| Piazuelo, E | 1 |
| Schneider, JL | 2 |
| Zhao, WK | 1 |
| Masclee, GM | 1 |
| Coloma, PM | 1 |
| Spaander, MC | 1 |
| Kuipers, EJ | 2 |
| Sturkenboom, MC | 1 |
| Goldberg, A | 1 |
| Gerkin, RD | 1 |
| Young, M | 1 |
| Beales, IL | 2 |
| Dearman, L | 2 |
| Vardi, I | 2 |
| Loke, Y | 1 |
| Thrift, AP | 3 |
| Anderson, LA | 2 |
| Murray, LJ | 2 |
| Cook, MB | 1 |
| Shaheen, NJ | 2 |
| Rubenstein, JH | 1 |
| Vaughan, TL | 1 |
| Whiteman, DC | 2 |
| Jankowski, J | 7 |
| Broughton, DE | 1 |
| Ozanne, E | 1 |
| Yachimski, P | 1 |
| Nishioka, NS | 2 |
| Gazelle, GS | 2 |
| Gatenby, PA | 1 |
| Ramus, JR | 1 |
| Caygill, CP | 1 |
| Winslet, MC | 1 |
| Watson, A | 1 |
| deCaestecker, J | 1 |
| Rizvi, S | 1 |
| Demars, CJ | 2 |
| Comba, A | 1 |
| Gainullin, VG | 1 |
| Rizvi, Z | 1 |
| Almada, LL | 1 |
| Lomberk, G | 1 |
| Fernández-Zapico, ME | 1 |
| Buttar, NS | 2 |
| Dall'Olmo, L | 1 |
| Moja, L | 1 |
| Jankowski, JA | 2 |
| Hooper, PA | 1 |
| Triadafilopoulos, G | 3 |
| Lombard, CM | 1 |
| Jobe, BA | 1 |
| Wang, F | 1 |
| Lv, ZS | 1 |
| Fu, YK | 1 |
| Scholl, S | 1 |
| Dellon, ES | 1 |
| Lee, SJ | 1 |
| Jung, MK | 1 |
| Kim, SK | 1 |
| Jang, BI | 1 |
| Lee, SH | 1 |
| Kim, KO | 1 |
| Kim, ES | 1 |
| Cho, KB | 1 |
| Park, KS | 1 |
| Kim, EY | 1 |
| Jung, JT | 1 |
| Kwon, JG | 1 |
| Lee, JH | 1 |
| Yang, CH | 1 |
| Park, CK | 1 |
| Seo, HE | 1 |
| Jeon, SW | 1 |
| Nicholson, A | 1 |
| Pandeya, N | 1 |
| Smith, KJ | 1 |
| Green, AC | 1 |
| Webb, PM | 1 |
| Omer, ZB | 1 |
| Ananthakrishnan, AN | 1 |
| Nattinger, KJ | 1 |
| Cole, EB | 1 |
| Lin, JJ | 1 |
| Thiagarajan, P | 1 |
| Sanders, DS | 1 |
| Grabsch, H | 1 |
| Bateman, A | 1 |
| Going, J | 1 |
| Goldin, R | 1 |
| Mapstone, N | 1 |
| Novelli, M | 1 |
| Walker, MM | 1 |
| Ziegler, KL | 1 |
| Romero, Y | 1 |
| Marcon, NE | 1 |
| Schnell, T | 1 |
| Sharma, P | 1 |
| Cruz-Correa, MR | 1 |
| Fleischer, DE | 1 |
| Chak, A | 1 |
| Devault, KR | 1 |
| Weinberg, DS | 1 |
| Della'Zanna, G | 1 |
| Richmond, E | 1 |
| Smyrk, TC | 1 |
| Mandrekar, SJ | 1 |
| Inadomi, JM | 1 |
| Thomson, AB | 1 |
| Barkun, AN | 1 |
| Armstrong, D | 1 |
| Chiba, N | 1 |
| White, RJ | 1 |
| Daniels, S | 1 |
| Escobedo, S | 1 |
| Chakraborty, B | 1 |
| Sinclair, P | 1 |
| Van Zanten, SJ | 1 |
| Füessl, HS | 2 |
| Garber, K | 1 |
| Raj, A | 1 |
| Kinoshita, Y | 1 |
| Yuki, T | 1 |
| Sharma, S | 1 |
| Siersema, PD | 1 |
| Yu, S | 1 |
| Sahbaie, P | 1 |
| Steyerberg, EW | 1 |
| Simpson, PW | 1 |
| Kaur, B | 1 |
| Sood, S | 1 |
| Traxler, B | 1 |
| Levine, D | 1 |
| Weston, A | 1 |
| Johnston, BT | 1 |
| Watson, RG | 1 |
| Murphy, SJ | 1 |
| Ferguson, HR | 1 |
| Comber, H | 1 |
| McGuigan, J | 1 |
| Reynolds, JV | 1 |
| Konturek, PC | 1 |
| Kania, J | 1 |
| Burnat, G | 1 |
| Hahn, EG | 1 |
| Leedham, S | 1 |
| Morgan, G | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-Blinded Phase II Trial of Esomeprazole Versus Esomeprazole + Two Doses of Aspirin in Barrett's Esophagus Patients[NCT00474903] | Phase 2 | 122 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The mean tissue PGE2 is reported for each Arm. (NCT00474903)
Timeframe: Baseline to 30 days after completion of study treatment
| Intervention | pg/mL (Mean) |
|---|---|
| Arm I (Placebo, Esomeprazole Magnesium) | -67.6 |
| Arm II (Low-dose Aspirin, Placebo, Esomeprazole Magnesium) | -123.9 |
| Arm III (Higher-dose Aspirin, Palcebo, Esomeprazole Magnesium) | -174.9 |
Toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to the interventional agent, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The number of patients reporting adverse events will be tabulated by grade. (NCT00474903)
Timeframe: Up to 30 days after completion of study treatment
| Intervention | participants (Number) | |
|---|---|---|
| Grade 3 or Higher | Grade 4 or Higher | |
| Arm I (Placebo, Esomeprazole Magnesium) | 0 | 0 |
| Arm II (Low-dose Aspirin, Placebo, Esomeprazole Magnesium) | 1 | 0 |
| Arm III (Higher-dose Aspirin, Palcebo, Esomeprazole Magnesium) | 1 | 0 |
13 reviews available for aspirin and Barrett Epithelium
| Article | Year |
|---|---|
Current Status of Chemoprevention in Barrett's Esophagus.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Chemoprevention; Drug Therapy, Combination; Esophageal N | 2021 |
Lifestyle interventions can reduce the risk of Barrett's esophagus: a systematic review and meta-analysis of 62 studies involving 250,157 participants.
Topics: Adenocarcinoma; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Aspirin; B | 2021 |
Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.
Topics: Aspirin; Barrett Esophagus; Cardiovascular Diseases; Colorectal Neoplasms; Drug Combinations; Gastro | 2014 |
Strategies to improve outcomes in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Aspirin; Barrett Esophagus; Combined Modality Therapy; Cytodi | 2014 |
Reduced Risk of Barrett's Esophagus in Statin Users: Case-Control Study and Meta-Analysis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-C | 2016 |
Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Disease Progres | 2016 |
Chemoprevention in Barrett's esophagus: A pill a day?
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Diet; Esophagea | 2011 |
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-Control St | 2011 |
Acid reflux and oesophageal cancer.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cyclooxygenase 2; Esophageal Neoplasms; Esophagitis; Gas | 2011 |
Aspirin and NSAIDs; benefits and harms for the gut.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cardiovascular Disease | 2012 |
Acid suppression and chemoprevention in Barrett's oesophagus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Enzyme Inhib | 2004 |
[Medical treatment of Barrett's esophagus].
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cycloo | 2005 |
Dilemmas in managing Barrett's oesophagus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Endoscopy, Gastrointestinal; Ga | 2006 |
6 trials available for aspirin and Barrett Epithelium
| Article | Year |
|---|---|
Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development.
Topics: Adenocarcinoma; Animals; Aspirin; Barrett Esophagus; Carcinogenesis; Cell Line, Tumor; Cell Prolifer | 2019 |
Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Drug A | 2018 |
Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cohort Studies; Demography; Eso | 2009 |
Comparing virtual with conventional microscopy for the consensus diagnosis of Barrett's neoplasia in the AspECT Barrett's chemoprevention trial pathology audit.
Topics: Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Disease Progression; Esomeprazole; Esophageal Neoplas | 2012 |
A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Barrett Esophagus; Biomarkers; Biopsy; Cyclooxygenase Inhib | 2012 |
The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett's oesophagus.
Topics: Adult; Aged; Aspirin; Barrett Esophagus; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhi | 2006 |
39 other studies available for aspirin and Barrett Epithelium
| Article | Year |
|---|---|
Barrett Esophagus: Rapid Evidence Review.
Topics: Adenocarcinoma; Anti-Inflammatory Agents; Aspirin; Barrett Esophagus; Esophageal Neoplasms; Humans; | 2022 |
Aspirin prevents NF-κB activation and CDX2 expression stimulated by acid and bile salts in oesophageal squamous cells of patients with Barrett's oesophagus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Bile Acids and Salts; CDX2 Tran | 2018 |
Aspirin: the miracle drug?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Female; Humans; Middle Ag | 2018 |
Should aspirin and PPIs be recommended for patients with Barrett's oesophagus?
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Esophageal Neoplasms; Esophagus; Humans; Proton Pump Inh | 2018 |
Chemoprevention of Barrett's oesophagus: a step closer with PPIs and aspirin.
Topics: Aspirin; Barrett Esophagus; Chemoprevention; Drug Combinations; Humans; Proton Pump Inhibitors; Rand | 2018 |
In Barrett esophagus, high- vs low-dose esomeprazole improved clinical outcomes; aspirin vs no aspirin did not.
Topics: Aspirin; Barrett Esophagus; Drug Therapy, Combination; Esomeprazole; Humans; Proton Pump Inhibitors | 2018 |
Will a Proton Pump Inhibitor and an Aspirin Keep the Doctor Away for Patients With Barrett's Esophagus?
Topics: Aspirin; Barrett Esophagus; Esomeprazole; Esophageal Neoplasms; Humans; Proton Pump Inhibitors | 2019 |
Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Aspirin; Barrett Esophagus; Case-Control Studies; Chemoprev | 2014 |
Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model.
Topics: Adenocarcinoma; Animals; Aspirin; Barrett Esophagus; Dinoprostone; Disease Models, Animal; Esophagea | 2014 |
Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; California; Case-C | 2015 |
NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-Control St | 2015 |
Medical Prevention of Barrett's Esophagus: Effects of Statins, Aspirin, Non-aspirin NSAIDs, Calcium, and Multivitamins.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Calcium; Case-Control Stu | 2015 |
Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-Cont | 2016 |
Chemoprevention and Barrett's esophagus: decisions, decisions.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Aspirin in the primary prevention of vascular disease.
Topics: Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Drug Therapy, Combination; Evidence-Based Medicine; H | 2009 |
Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cell Growth Processes; | 2010 |
Treatment for non-dysplastic Barrett's oesophagus: a well-informed, demanding patient.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Fundoplication; Humans; Male; M | 2010 |
"War and Peace" with Barrett's esophagus.
Topics: Adenocarcinoma; Aged; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Barrett Esophagus; Celeco | 2011 |
Treatment of GERD and proton pump inhibitor use in the elderly: practical approaches and frequently asked questions.
Topics: Adenocarcinoma; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Aspirin; Barrett Esop | 2011 |
[Clinical characteristics of gastroesophageal reflux disease with esophageal injury in korean: focusing on risk factors].
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Aspiri | 2011 |
The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus.
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Ster | 2011 |
Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis.
Topics: Aged; Anti-Inflammatory Agents; Aspirin; Barrett Esophagus; Case-Control Studies; Chemoprevention; F | 2012 |
Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett E | 2012 |
Is 325 mg of prevention worth a pound of cure?
Topics: Aspirin; Barrett Esophagus; Cyclooxygenase Inhibitors; Dinoprostone; Female; Humans; Male; Omeprazol | 2012 |
The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barret | 2003 |
[Heartburn without esophagitis. Symptoms more important than the finding?].
Topics: Androstadienes; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ul | 2003 |
Aspirin for cancer chemoprevention: still a headache?
Topics: Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cost-Benefit Analysis; Cyclooxygenase Inhibitor | 2004 |
Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
Topics: Aged; Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cost-Benefit Analysis; Drug Costs; Esopha | 2004 |
Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
Topics: Adenocarcinoma; Adult; Aged; Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Cost-Benefit Analysis; D | 2004 |
Upper gastrointestinal bleeding after hip and knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplast | 2006 |
Colorectal neoplasia in veterans is associated with Barrett's esophagus but not with proton-pump inhibitor or aspirin/NSAID use.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Biopsy; California; Color | 2006 |
Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
Topics: Acetaminophen; Adenocarcinoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Asp | 2006 |
NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Barrett Esophagus; Casp | 2006 |
The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus--the good, the bad, and the flawed!
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Chemoprevent | 2007 |
Biomarkers identified to predict esophageal cancer susceptibility and aspirin found to lower cancer risk.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Biomarkers, Tum | 2007 |
[Family practice highlights of stomach, liver and intestinal reference points. Your arsenal against abdominal problems].
Topics: Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Family Practi | 2007 |
Relationship between colorectal and esophageal cancer.
Topics: Aspirin; Barrett Esophagus; Colorectal Neoplasms; Esophageal Neoplasms; Humans | 1996 |
Correspondence re: R. Kim et al., Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol., Biomark. Prev., 6: 369-377, 1997.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cell Transforma | 1998 |